Resumed Underweight X

NVTA Invitae

JP Morgan

Downgrades Mkt Perform Underperform X

NVTA Invitae

Raymond James

Downgrades Neutral Sell X

NVTA Invitae

Goldman

$2

Initiated Underperform X

NVTA Invitae

Credit Suisse

$1

Downgrades Neutral Underweight X

NVTA Invitae

JP Morgan

Downgrades Outperform Mkt Perform X

NVTA Invitae

Cowen

$8 $2.50

Downgrades Buy Neutral X

NVTA Invitae

Ladenburg Thalmann

Downgrades Outperform Mkt Perform X

NVTA Invitae

SVB Leerink

Downgrades Buy Hold X

NVTA Invitae

The Benchmark Company

Initiated Underweight X

NVTA Invitae

Piper Sandler

$2.50

Initiated Outperform X

NVTA Invitae

Raymond James

$37

Initiated Neutral X

NVTA Invitae

Goldman

$33

Initiated Equal Weight X

NVTA Invitae

Wells Fargo

$30

Upgrades Perform Outperform X

NVTA Invitae

Oppenheimer

$48

Upgrades Neutral Buy X

NVTA Invitae

Ladenburg Thalmann

$46.50 $58

Downgrades Outperform Perform X

NVTA Invitae

Oppenheimer

Reiterated Buy X

NVTA Invitae

The Benchmark Company

$26 $28

Initiated Buy X

NVTA Invitae

Chardan Capital Markets

$29

Initiated Outperform X

NVTA Invitae

Oppenheimer

Resumed Buy X

NVTA Invitae

The Benchmark Company

$17

Reiterated Buy X

NVTA Invitae

The Benchmark Company

$11 $10

NVTA  Invitae Corporation

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.